| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1185/030079901753403126 |
| P698 | PubMed publication ID | 11922396 |
| P50 | author | Stephen Holgate | Q1547900 |
| P2093 | author name string | Liu J | |
| Bousquet J | |||
| Wenzel S | |||
| Fox H | |||
| Castellsague J | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| antibody | Q79460 | ||
| allergic asthma | Q12301086 | ||
| P304 | page(s) | 233-240 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Current Medical Research and Opinion | Q5195063 |
| P1476 | title | Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. | |
| P478 | volume | 17 |
| Q36642971 | A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma |
| Q36765775 | Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma |
| Q24247152 | Anti-IgE for chronic asthma in adults and children |
| Q35680624 | Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma |
| Q90353156 | Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells |
| Q34412092 | Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy |
| Q36834564 | Anti-immunoglobulin e therapy |
| Q37909907 | Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? |
| Q47387899 | Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. |
| Q44924019 | Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. |
| Q36951998 | Immunoglobulin E blockade in the treatment of asthma |
| Q89912162 | Long-term effect of antifungal therapy for the treatment of severe resistant asthma: an active comparator clinical trial |
| Q30716893 | Omalizumab and the immune system: an overview of preclinical and clinical data. |
| Q36348627 | Omalizumab: a monoclonal anti-IgE antibody |
| Q33973970 | Omalizumab: the evidence for its place in the treatment of allergic asthma |
| Q46299846 | Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study |
| Q40740336 | Severe asthma and the omalizumab option. |
| Q36587363 | Targeted IgE Therapy for Patients With Moderate to Severe Asthma. |
| Q47856691 | Targeting immunoglobulin E as a novel treatment for asthma |
| Q35553420 | The need for pediatric studies of allergy and asthma medications |
| Q41577766 | The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. |
| Q30801642 | Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review |
| Q37754792 | Use of biologicals as immunotherapy in asthma and related diseases |
| Q81345914 | [Anti IgE antibodies for the treatment of difficult asthma] |
| Q81574964 | [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine] |
Search more.